Core Viewpoint - Company Gilead Sciences-B (01672) has made significant strategic adjustments to its pipeline for 2024, terminating its viral disease treatment pipeline and introducing new clinical pipelines for obesity and metabolic diseases [1][2] Group 1: Strategic Adjustments - The company has decided to terminate its pipeline for viral diseases, including products for chronic hepatitis B, HIV, and RSV, as well as the clinical advancement of the MASH treatment product ASC41 [1] - New clinical pipelines have been introduced for obesity and metabolic diseases, specifically the GLP receptor agonist ASC30 and the THR-β agonist ASC47, both of which have progressed to Phase I clinical trials overseas by the end of 2024 [1] Group 2: Financial Overview - The company's R&D expenditure is expected to increase by 39.5% year-on-year to 302 million yuan in 2024, with nearly 100 million yuan allocated for metabolic disease research and approximately 80 million yuan for acne treatment products entering Phase III clinical trials [1] - The company has approximately 1.98 billion yuan in cash and cash equivalents, which is projected to support its R&D and operations until 2029 [1] Group 3: Clinical Trial Results - The company is conducting multiple Phase I clinical trials related to obesity, including ASC30, which has shown an average weight reduction of 4.2% and 6.2% relative to baseline after 28 days of treatment in two patient cohorts [2] - ASC30 has a long half-life of up to 40 days in animal models, while ASC47 has demonstrated a half-life of 26 days in healthy subjects and 40 days in obese patients, with a peak weight reduction of 1.7% observed on day 50 after a single 90 mg subcutaneous injection [2] - The initial results of the oral and subcutaneous weight loss products indicate superior weight reduction effects and long half-lives, providing a unique advantage over competing products in the same category [2]
港股异动 | 歌礼制药-B(01672)早盘涨超12% 去年公司管线做出重大战略调整 减肥药物效果优异